FOI Request
- Disclosure ID
- FOI/00964
- Request Date
- May 12, 2016
- Subject
- Oncology Drugs
- Description
Within your trust how many unique patients with Advanced Prostate Cancer (C61X) have been treated in the past 12 months?
How many patients with Advanced Prostate Cancer have received?
Abiraterone (Zytiga) Cabazitaxel (Jevtana) Docetaxel (Taxotere) Enzalutamide (Xtandi) Radium-223 (Xofigo) Bicalutamide (Casodex) Within your trust how many unique patients with Hepatocellular Carcinoma (C220) have been treated in the past 12 months?
How many patients with with Hepatocellular Carcinoma have received?
Bevacizumab (Avastin) Everolimus (Afinitor) Lapatinib (Tyverb) Sorafenib (Nexavar) Sunitinib (Sutent) Within your trust how many unique patients with Gastrointestinal Stromal Tumours (C269) have been treated in the past 12 months?
How many patients with with Gastrointestinal Stromal Tumours have received?
Dasatinib (Sprycel) Imatininb (Glivec) Nilotinib (Tasigna) Pazopanib (Votrient) Regorafenib (Stivarga) Sorafenib (Nexavar) Sunitinib (Sutent)
- Response
Unfortunately the Pharmacy IT system doesn’t store the clinical indication, we have supplied the quantities and attached a spreadsheet which breaks it down by month.
Chemical Total Abiraterone Acetate 44,630 Bevacizumab 266 Bicalutamide 10,437 Cabazitaxel 6 Dasatinib 3,191 Docetaxel 512 Enzalutamide 60,228 Everolimus 1,350 Nilotinib 7,244 Pazopanib 4,505 Sorafenib 1,596 Sunitinib 2,579